Filing Details
- Accession Number:
- 0001140361-24-039821
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-30 21:02:08
- Reporting Period:
- 2024-08-29
- Accepted Time:
- 2024-08-30 21:02:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1368514 | Adma Biologics Inc. | ADMA | Biological Products, (No Disgnostic Substances) (2836) | 562590442 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1542519 | B Jerrold Grossman | C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-08-29 | 118,861 | $3.66 | 586,166 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-08-29 | 9,000 | $5.96 | 595,166 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-08-29 | 9,000 | $10.80 | 604,166 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-08-29 | 136,861 | $17.27 | 467,305 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock | Disposition | 2024-08-29 | 118,861 | $3.66 | 118,861 | $3.66 |
Common Stock | Common Stock | Disposition | 2024-08-29 | 9,000 | $5.96 | 9,000 | $5.96 |
Common Stock | Common Stock | Disposition | 2024-08-29 | 9,000 | $10.80 | 9,000 | $10.80 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2027-06-06 | No | 4 | M | Direct | |
0 | 2026-01-28 | No | 4 | M | Direct | |
0 | 2025-01-30 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 22,857 | Indirect | See Footnote |
Common Stock | 31,381 | Indirect | See Footnote |
Common Stock | 38,294 | Indirect | See Footnote |
Common Stock | 175 | Indirect | See Footnote |
Footnotes
- The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person.
- These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
- These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
- These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
- These shares are owned by the reporting person's wife.
- These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019.
- These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.
- These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.
- The Reporting Person is exercising these options due, in part, to their near-term expiration date.